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Introduction {#sec001}
============

A lot of evidence has indicated that percutaneous coronary intervention (PCI) is not inferior to coronary artery bypass grafting in patients with left main coronary artery disease (LM CAD), especially in those with low-moderate anatomical complexity\[[@pone.0179756.ref001]--[@pone.0179756.ref004]\]. Thus, current guidelines recommend PCI as an alternative to surgical revascularization in certain LM CAD groups \[[@pone.0179756.ref005]\].

Intravascular ultrasound has been widely used in the era of drug-eluting stents (DES) because it provides more accurate and comprehensive assessment of the structure of coronary arteries. A recent meta-analysis of 15 trials found that intravascular ultrasound (IVUS)-guided PCI significantly reduced the risk of major adverse cardiac events (MACEs) compared with angiography-guided PCI for both first and second generations of DES\[[@pone.0179756.ref006]\]. Another individual level meta-analysis of three randomized controlled trials (RCTs) reported that IVUS-guided PCI is associated with favorable outcomes in patients with long lesions or chronic total occlusion lesions \[[@pone.0179756.ref007]\].

Current guidelines recommend that IVUS be used to assess the severity and optimize the treatment of unprotect LMCA lesions (Class IIa, level of evidence B) \[[@pone.0179756.ref005]\]. Several new studies addressing this issue have been published in the past few years. Thus, we conducted a meta-analysis of all the studies comparing IVUS-guided and angiography-guided PCI to determine the effect of IVUS on mortality in patients with LM CAD.

Materials and methods {#sec002}
=====================

The methods of this meta-analysis were pre-specified. The protocol was registered in PROSPERO (international prospective registration of systematic reviews; Registration number: CRD 42017055134). The reporting was consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([S1 File](#pone.0179756.s002){ref-type="supplementary-material"})\[[@pone.0179756.ref008]\].

Data sources and searches {#sec003}
-------------------------

Systematic searches of the MEDLINE (1950 to December 2016), EMBASE (1966 to December 2016), and Cochrane Central Register of Controlled Trials (Issues 1 of 12, December 2016) were conducted to identify all studies that assessed the effect of IVUS-guided LM PCI on mortality compared with that of angiography-guided PCI. Furthermore, a manual search of the references of published reviews and meta-analyses was performed. The key words for the database searches included "left main" and "intravascular ultrasound".

Study selection {#sec004}
---------------

The eligibility of a study was determined independently by two authors (Y. Y. and Y. Z.). The inclusion criteria for this meta-analysis were: (1) study design: randomized or non-randomized; (2) study population: patients with LM CAD; (3) intervention: IVUS-guided PCI; (4) control: angiography-guided PCI; and (5) outcomes: all-cause death and/or cardiac death. Studies published as full length articles and conference abstracts were included. The exclusion criteria included: (1) non-English literature; and (2) studies included both LM and non LM CAD patients. The primary outcome of the meta-analysis was mortality (all-cause death and cardiac death), whereas the secondary outcomes included myocardial infarction \[MI\], target vessel revascularization \[TVR\], target lesion revascularization \[TLR\], and definite or probable in-stent thrombosis \[IST\].

Data extraction {#sec005}
---------------

The following information was extracted independently from the included studies in a pre-specified manner by two authors (Y. Y. and Y. Z.) and included the following: (1) study design; (2) number of participants; (3) characteristics of the study population (including age, gender, mean body mass index, smoking status, hypertension, diabetes, smoking, previous cardiovascular disease, left ventricular ejection fraction, and types of LM lesions); and (4) study outcomes (all-cause death, cardiac death, MI, TVR, TLR, and IST).

Study quality assessment {#sec006}
------------------------

The methodological quality of the eligible studies (only full-length publications, both) was assessed independently by two authors (Y. Y. and Y. Z.) using the modified Downs and Black instrument, which can be used for both randomized and non-randomized studies \[[@pone.0179756.ref009], [@pone.0179756.ref010]\]. This instrument consists of 26 items distributed between five subscales: reporting (9 items), external validity (3 items), bias (7 items), confounding (6 items), and power (1 items). In the modified instrument, answers are scored 0 or 1, except for one item in the reporting subscale, which is scored 0 to 2. The total maximum score is 27 \[[@pone.0179756.ref010]\].

Data synthesis and analysis {#sec007}
---------------------------

For randomized studies, the intention to treat data were used for analysis. For non-randomized studies, propensity score matching data were used for the meta-analysis unless they were unavailable. Pooled relative risks (RRs) were calculated using a random effects model with inverse variance method\[[@pone.0179756.ref011]\]. *I*^2^ statistics were used to assess the heterogeneity among the included studies\[[@pone.0179756.ref012]\]. Furthermore, subgroup analyses were used to explore the sources of heterogeneity with the following predefined covariates: (1) types of studies (unadjusted non-randomized studies, RCT, or propensity score-matched non-randomized studies); (2) study population (Asia or non-Asia); and (3) duration of follow-up (\<3 years or ≥3 years). A cumulative meta-analysis was performed to determine the treatment effectiveness of IVUS-guided PCI by accumulation in chronological order. Sensitivity analysis was used to explore the degree to which the pooled RR for a primary outcome was affected in a conference abstract. Begg\'s funnel plot and Egger weighted regression statistic were used to assess the publication bias \[[@pone.0179756.ref013], [@pone.0179756.ref014]\]. All analyses were performed using RevMan software (Review Manager 5.3, The Cochrane Collaboration, Copenhagen, Denmark) and STATA software (version 11.0; Stata Corp, College Station, TX). All statistical tests were two-sided, and a p-value \<0.05 was considered statistically significant.

Results {#sec008}
=======

Study identification {#sec009}
--------------------

The initial literature search identified 538 studies. Ten studies (1 randomized controlled trial and 9 non-randomized studies) were included in the meta-analysis based on fulfillment of the inclusion criteria \[[@pone.0179756.ref015]--[@pone.0179756.ref024]\]. A flowchart of study identification and screening is presented in [Fig 1](#pone.0179756.g001){ref-type="fig"}. Of the 10 included studies, 5 studies were reported as conference abstracts \[[@pone.0179756.ref016]--[@pone.0179756.ref019], [@pone.0179756.ref024]\]. Propensity score data were available in 4 non-randomized studies \[[@pone.0179756.ref015], [@pone.0179756.ref020], [@pone.0179756.ref021], [@pone.0179756.ref023]\]. Five studies reported both all-cause death and cardiac death \[[@pone.0179756.ref018]--[@pone.0179756.ref020], [@pone.0179756.ref022], [@pone.0179756.ref024]\], whereas 4 studies reported only all-cause death \[[@pone.0179756.ref015]--[@pone.0179756.ref017], [@pone.0179756.ref023]\] and 1 study reported only cardiac death\[[@pone.0179756.ref021]\]. The total sample size of the included patients was 6,480, of which 2,778 patients were assigned to the IVUS-guided PCI group and 3,702 patients were assigned to the angiography-guided PCI group. The information of included studies and the baseline characteristics of participants in each full-length publication are tabulated in Tables [1](#pone.0179756.t001){ref-type="table"} and [2](#pone.0179756.t002){ref-type="table"}, respectively. The characteristics of lesion and procedure are presented in [Table 3](#pone.0179756.t003){ref-type="table"}. The results of study quality assessment are summarized in [S1 Table](#pone.0179756.s001){ref-type="supplementary-material"}.

![Flow chart of study selection.](pone.0179756.g001){#pone.0179756.g001}

10.1371/journal.pone.0179756.t001

###### Characteristics of the included studies.

![](pone.0179756.t001){#pone.0179756.t001g}

  Study                                                              Publication type   Design           Type of data included in meta-analysis   Primary outcome in each study   Follow-up, years   All-cause mortality   Cardiac mortality                                 
  ------------------------------------------------------------------ ------------------ ---------------- ---------------------------------------- ------------------------------- ------------------ --------------------- ------------------- ------ ---- ----- ---- ------ ----
  Park SJ, et al. 2009 \[[@pone.0179756.ref015]\]                    Full-length        Non-randomized   Propensity score-matched                 Death                           3                  145                   9                   145    23   /     /    /      /
  Kinoshita N, et al. 2010 \[[@pone.0179756.ref016]\]                Abstract           Non-randomized   Unadjusted                               Not specified                   2                  228                   2                   226    8    /     /    /      /
  Jama A, et al.2011 \[[@pone.0179756.ref017]\]                      Abstract           Non-randomized   Unadjusted                               Death                           3                  111                   18                  184    25   /     /    /      /
  Narbute I, et al. 2012 \[[@pone.0179756.ref018]\]                  Abstract           Non-randomized   Unadjusted                               Death                           1                  294                   13                  671    47   294   9    671    42
  Park SH, et al. 2012 \[[@pone.0179756.ref019]\]                    Abstract           Non-randomized   Unadjusted                               Not specified                   2                  90                    5                   92     15   90    2    92     12
  De La Torre Hernandez JM, et al. 2014 \[[@pone.0179756.ref020]\]   Full-length        Non-randomized   Propensity score-matched                 Cardiac death/MI/TLR            3                  505                   37                  505    66   505   17   505    30
  Gao XF, et al. 2014 \[[@pone.0179756.ref021]\]                     Full-length        Non-randomized   Propensity score-matched                 Cardiac death/MI/TVR            1                  /                     /                   /      /    291   5    291    15
  Tan Q, et al. 2015 \[[@pone.0179756.ref022]\]                      Full-length        Randomized       Intention to treat                       Death/MI/TLR                    2                  61                    2                   62     3    61    2    62     3
  Tang Y, et al. 2016 \[[@pone.0179756.ref024]\]                     Abstract           Non-randomized   Unadjusted                               Death/MI                        3                  713                   16                  1186   45   713   9    1186   31
  Andell P, et al. 2017 \[[@pone.0179756.ref023]\]                   Full-length        Non-randomized   Propensity score-matched                 Death/ISR/IST                   10                 340                   37                  340    63   /     /    /      /

MI = myocardial infarction; TVR = target vessel revascularization; TLR = target lesion revasculariztion.

10.1371/journal.pone.0179756.t002

###### Characteristics of participants in each included full-length publication.

![](pone.0179756.t002){#pone.0179756.t002g}

  Study                                                              Age, years   Male, %   HTN, %   DM, %   Smoker, %   Prior PCI, %   Prior MI, %   CRF, %   ACS, %   LVEF, %   LM distal, %
  ------------------------------------------------------------------ ------------ --------- -------- ------- ----------- -------------- ------------- -------- -------- --------- --------------
  Park SJ, et al. 2009 \[[@pone.0179756.ref015]\]                    64.8         70.9      54.7     33.1    22.4        22.1           8.5           3.0      61.2     61.4      53.0
  De La Torre Hernandez JM, et al. 2014 \[[@pone.0179756.ref020]\]   66.5         79.4      66       35.4    30.6        21.6           24.9          6.5      60.0     55.1      44.2
  Gao XF, et al. 2014 \[[@pone.0179756.ref021]\]                     66.7         78.7      72.1     33.6    33.6        17.6           18.0%         29.7     /        57.4      86.4
  Tan Q, et al. 2015 \[[@pone.0179756.ref022]\]                      76.2         65.9      68.3     31.7    45.5        18.9           /             /        68.3     54.3      53.7
  Andell P, et al. 2017 \[[@pone.0179756.ref023]\]                   71.5         72.4      73.5     24.6    13.6        33.3           34.7          3.2      64.7     /         /

HTN = hypertension; DM = diabetes mellitus; PCI = percutaneous coronary intervention; MI = myocardial infarction; CRF = chronic renal failure; ACS = acute coronary syndrome; LVEF = left ventricular ejection fraction; LM = left main.

10.1371/journal.pone.0179756.t003

###### Characteristics of lesions and procedure in each included full-length publication.

![](pone.0179756.t003){#pone.0179756.t003g}

  Study                                                              Intervention   LM lesion   Extent of diseased vessel   Complex stenting                        
  ------------------------------------------------------------------ -------------- ----------- --------------------------- ------------------ ------ ------ ------ ------
  Park SJ, et al. 2009 \[[@pone.0179756.ref015]\]                    IVUS-guided    46.3        53.7                        13.9               26.4   29.4   30.4   22.4
  Angiography-guided                                                 47.8           52.2        14.4                        22.4               30.9   32.3   22.4   
  De La Torre Hernandez JM, et al. 2014 \[[@pone.0179756.ref020]\]   IVUS-guided    56.3        43.7                        /                  /      31.7   31.9   12.5
  Angiography-guided                                                 55.3           44.7        /                           /                  33.2   29.5   12.2   
  Gao XF, et al. 2014 \[[@pone.0179756.ref021]\]                     IVUS-guided    14.2        85.8                        /                  /      /      /      45.7
  Angiography-guided                                                 13.1           86.9        /                           /                  /      /      41.2   
  Tan Q, et al. 2015 \[[@pone.0179756.ref022]\]                      IVUS-guided    47.5        52.5                        11.5               23.0   39.3   26.2   40.3
  Angiography-guided                                                 45.2           54.8        16.1                        21.0               35.5   27.4   41.9   
  Andell P, et al. 2017 \[[@pone.0179756.ref023]\]                   IVUS-guided    30.9        69.1                        9.4                35.0   34.7   20.9   /
  Angiography-guided                                                 30.9           69.1        10.0                        36.2               34.7   19.1   /      

*p* for all intergroup difference in each study \> 0.05; LM = left main; VD = vessel disease.

Quantitative data analysis {#sec010}
--------------------------

For the primary outcomes, IVUS-guided PCI significantly reduced the risk of all-cause death compared with angiography-guided PCI (RR 0.60, 95% confidence interval \[CI\] 0.47--0.75, p\<0.001; [Fig 2A](#pone.0179756.g002){ref-type="fig"}) with moderate heterogeneity (χ^2^ = 9.89, I^2^ = 19%, p for heterogeneity = 0.27). In addition, IVUS-guided PCI was associated with a lower risk of cardiac death compared with angiography-guided PCI (RR 0.47, 95% CI 0.33--0.66, p\<0.001; [Fig 2B](#pone.0179756.g002){ref-type="fig"}). There was no statistically significant heterogeneity across the included studies (χ^2^ = 2.87, I^2^ = 0%, p for heterogeneity = 0.72).

![Forest plot of primary outcomes; (A) all-cause death; (B) cardiac death.](pone.0179756.g002){#pone.0179756.g002}

For the secondary outcomes, IVUS-guided PCI was associated with lower risks of TLR (RR 0.43, 95% CI 0.25--0.73, p = 0.002; I^2^ = 0%, p for heterogeneity = 0.53) and definite or probable IST (RR 0.28, 95% CI 0.12--0.67, p = 0.004; I^2^ = 5%, *p* for heterogeneity = 0.37) compared with angiography-guided PCI. However, there were no differences in the risks of MI and TVR between the two groups ([Table 4](#pone.0179756.t004){ref-type="table"}).

10.1371/journal.pone.0179756.t004

###### Pooled results for secondary outcomes.

![](pone.0179756.t004){#pone.0179756.t004g}

  Secondary outcome                 Number of studies   IVUS-guided group   Angiography-guided group   RR     95% CI       p for RR   I^2^   p for heterogeneity
  --------------------------------- ------------------- ------------------- -------------------------- ------ ------------ ---------- ------ ---------------------
  Myocardial infarction             7                   114/1916            181/2465                   0.8    0.61--1.06   0.12       22%    0.26
  Target vessel revascularization   6                   147/1972            191/2445                   0.89   0.66--1.20   0.44       47%    0.09
  Target lesion revascularization   3                   18/442              43/445                     0.43   0.25--0.73   0.002      0%     0.53
  In-stent thrombosis               4                   7/1197              37/1198                    0.28   0.12--0.67   0.004      5%     0.37

IVUS = intravascular ultrasound; RR = risk ratio; CI = confidence interval

In the pre-specified subgroup analyses, there were no significant interactions between subgroups regarding the types of study, study population, or length of follow-up (all *p* for subgroup differences \>0.05; [Fig 3](#pone.0179756.g003){ref-type="fig"}). Cumulative meta-analysis indicated that there was a consistent beneficial effect of IVUS-guided PCI since 2012 ([Fig 4](#pone.0179756.g004){ref-type="fig"}). Sensitivity analysis showed that the pooled RRs, excluding conference abstract data, were comparable (RR 0.56, 95% CI 0.44--0.70, p\<0.001; I^2^ = 0%, p for heterogeneity = 0.90), indicating the final results were not affected by inclusion of conference abstracts.

![Results of subgroup analyses.](pone.0179756.g003){#pone.0179756.g003}

![Results of cumulative meta-analysis in chronological order.](pone.0179756.g004){#pone.0179756.g004}

Both Begg's test (p = 0.532) and Egger weighted regression statistic (p = 0.587) suggested no significant publication bias across the studies.

Discussion {#sec011}
==========

Our meta-analysis of 10 studies indicated that PCI under IVUS guidance for LM CAD could reduce the risk of all-cause mortality by 40% and cardiac death by 53% compared with conventional angiography-guided PCI. In addition, IVUS-guided PCI in LM CAD was associated with lower risks of TLR and IST.

Park et al. first found that guidance with IVUS may optimize the immediate outcome achieved with a larger lumen diameter in comparison to not using IVUS guidance in selected patients receiving unprotected LM stenting \[[@pone.0179756.ref025]\]. Agostoni et al. first assessed the effect of IVUS on the early clinical outcomes in 58 patients who underwent PCI for LM CAD. Due to the small sample size, there study was unable to report a statistical difference in the risk of MACEs (8% in IVUS group versus 20% in non IVUS group, p = 0.18) \[[@pone.0179756.ref026]\]. Park et al's study from the MANI-COMPARE registry was the first to demonstrate the possible benefits of IVUS guidance for reducing long-term mortality associated with PCI for unprotected LM CAD\[[@pone.0179756.ref015]\], and this study is the major reference for the recommendation in current guidelines. Indeed, several studies have been published since then, and most of them reported a similar conclusion. Our cumulative meta-analysis indicated that the beneficial effect of IVUS-guidance in LMCA PCI has become consistent since the publication of Narbute *et al*. in 2012. This may justify modification of the level of evidence in guidelines.

To date, there has been only one small randomized controlled trial comparing IVUS-guided with angiography-guided PCI in LM CAD. Most sources of evidence came from non-randomized studies. Because the characteristics of participants in the two groups would be quite different in this situation, controlling for confounding factors becomes one of the major issues when conducting a meta-analysis of non-randomized studies\[[@pone.0179756.ref027]\]. Propensity score matching is a statistical technique as powerful as regression for confounder adjustment when estimating a treatment effect\[[@pone.0179756.ref028]\]. In the subgroup analyses, pooled results from propensity score-matched studies and randomized controlled trials were found to be similar with those from unadjusted non-randomized studies, indicating that the conclusion was less likely to be compromised by the confounding effect of the non-randomized studies.

The role of IVUS in complex PCI have been investigated by several studies. Previous studies have reported that IVUS is a valuable tool for recanalization of the chronic total occlusion (CTO) \[[@pone.0179756.ref029], [@pone.0179756.ref030]\] and IVUS-guided CTO intervention have been proved to be associated with lower 12-month major adverse cardiac event rate \[[@pone.0179756.ref031]\]. A recent meta-analysis of eight RCT have confirmed the IVUS-guided PCI could significantly reduce the risk of major adverse cardiac events and target lesion/vessel revascularization in patients with complex lesion, such as CTO and long coronary lesions\[[@pone.0179756.ref032]\]. The mechanisms by which IVUS-guided PCI improves survival in LM CAD are still uncertain and may be associated with pre-PCI and post-PCI assessments.

Although angiography was considered the 'gold standard' for coronary artery assessment, the severity of atherosclerosis might be misjudged due to significant inter- and intra-observer variability \[[@pone.0179756.ref033]--[@pone.0179756.ref035]\]. In a study of IVUS by Oviedo et al., the positive predictive values of angiography (diameter stenosis \>50% or "1" in the Medina classification) for identifying an IVUS plaque burden \>70% or a reduction in minimum lumen area (\<4.0 mm^2^ for the ostial LAD or LCX artery and \<6.0 mm^2^ for the distal LMCA) were only 35.1% and 56.7%, respectively \[[@pone.0179756.ref036]\]. Thus, angiographic assessment of LMCA bifurcation lesions was rarely accurate, which could lead to use of undesirable strategies. Although there is no evidence from RCT, the single-stent technique could be considered as the default strategy for bifurcation LM lesions in selected patients, such as insignificant ostial LCX stenosis or non-left dominant coronary system \[[@pone.0179756.ref037], [@pone.0179756.ref038]\]. IVUS provides more accurate information of the disease status of the distal LM complex, especially the LCX ostium. Kang et al found that an IVUS-derived minimal lumen of \>3.7 mm^2^ or plaque burden of \<56% in the LCX ostium can exclude functional LCX compromise (fractional flow reserve \<0.80) after main vessel stenting with single stent technique \[[@pone.0179756.ref039]\].

For post-PCI assessment, a comprehensive study of IVUS by Kang et al. found that the stent area in the LMCA was associated with in-stent restenosis (ISR) and clinical outcomes \[[@pone.0179756.ref040]\]. The cutoffs that best predicted ISR were 5.0 mm^2^, 6.3 mm^2^, 7.2 mm^2^, and 8.2 mm^2^ for the ostial LCX, ostial LAD, polygon of confluence, and distal LM, respectively. Clinical outcomes might be improved by IVUS optimization during LMCA stenting procedures with these criteria \[[@pone.0179756.ref040]\]. Furthermore, the results of this meta-analysis have suggested a reduction in the risk of IST with IVUS-guided PCI. It is reported that when performing double-kissing (DK) crush, IVUS-guided procedure could improve the procedural quality (less malaposition, edge dissection, and stent expansion) and was associated with a decrease IST, resulting in a significant decrement of ST-elevation MI \[[@pone.0179756.ref041]\].

There were several limitations in the current study. First, this was a study-level meta-analysis instead of a patient-level meta-analysis, and thus, we could not assess the effect of all different factors on the conclusion. Second, this meta-analysis included mainly non-randomized studies. We believe these conclusion could provide fundamental information for the future RCT. Third, Although our subgroup analysis of propensity score-matched studies confirmed the conclusion, unmeasured confounders may have influenced the outcomes. Finally, some important characteristics of the patients such as SANTAX scores were not reported in the included studies. Also, the included conference abstracts provided limited information on the patient and lesion characteristics.

Conclusions {#sec012}
===========

This meta-analysis suggested that IVUS-guided PCI is superior to angiography-guided PCI in LMCA PCI, based on reductions in the risks of both all-cause and cardiac death. Still, a larger scale RCT should be conducted to confirm these conclusions.
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